These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 31741142

  • 1. Understanding Chronic Aggression and Its Treatment in Children and Adolescents.
    Magalotti SR, Neudecker M, Zaraa SG, McVoy MK.
    Curr Psychiatry Rep; 2019 Nov 18; 21(12):123. PubMed ID: 31741142
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response.
    Arnold LE, Gadow KD, Farmer CA, Findling RL, Bukstein O, Molina BS, Brown NV, Li X, Rundberg-Rivera EV, Bangalore S, Buchan-Page K, Hurt EA, Rice R, McNamara NK, Aman MG.
    J Child Adolesc Psychopharmacol; 2015 Apr 18; 25(3):203-12. PubMed ID: 25885010
    [Abstract] [Full Text] [Related]

  • 5. Attendance and Engagement in Parent Training Predict Child Behavioral Outcomes in Children Pharmacologically Treated for Attention-Deficit/Hyperactivity Disorder and Severe Aggression.
    Joseph HM, Farmer C, Kipp H, Kolko D, Aman M, McGinley J, Arnold LE, Gadow KD, Findling RL, Molina BSG.
    J Child Adolesc Psychopharmacol; 2019 Mar 18; 29(2):90-99. PubMed ID: 30592635
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
    Aman MG, Binder C, Turgay A.
    J Child Adolesc Psychopharmacol; 2004 Mar 18; 14(2):243-54. PubMed ID: 15319021
    [Abstract] [Full Text] [Related]

  • 8. Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder.
    Farmer CA, Brown NV, Gadow KD, Arnold LE, Kolko DG, Findling RL, Molina BS, Buchan-Page KA, Rice RR, Bangalore SS, Bukstein O, Rundberg-Rivera EV, McNamara N, Aman MG.
    J Child Adolesc Psychopharmacol; 2015 Apr 18; 25(3):213-24. PubMed ID: 25885011
    [Abstract] [Full Text] [Related]

  • 9. The Relationship between Acute Dyskinesia with a Single Dose of Methylphenidate and Recent Risperidone Discontinuation in a Child with Attention-Deficit/Hyperactivity Disorder.
    Ince E, Algedik P, Demirdogen ES, Emul M, Demir T.
    J Child Adolesc Psychopharmacol; 2015 May 18; 25(4):378-9. PubMed ID: 25920038
    [No Abstract] [Full Text] [Related]

  • 10. Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression.
    Rundberg-Rivera EV, Townsend LD, Schneider J, Farmer CA, Molina BB, Findling RL, Gadow KD, Bukstein OG, Arnold LE, Kolko DJ, Buchan-Page KA, McNamara NK, Michel C, Austin A, Kipp H, Rice RR, Aman MG.
    J Child Adolesc Psychopharmacol; 2015 Apr 18; 25(3):225-33. PubMed ID: 25885012
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment.
    Elbe D, Barr AM, Honer WG, Procyshyn RM.
    J Psychiatry Neurosci; 2014 May 18; 39(3):E32-3. PubMed ID: 24758945
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Medications used in the treatment of disruptive behavior in children with FASD--a guide.
    Ozsarfati J, Koren G.
    J Popul Ther Clin Pharmacol; 2015 May 18; 22(1):e59-67. PubMed ID: 25715382
    [Abstract] [Full Text] [Related]

  • 18. Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder.
    West AE, Weinstein SM, Celio CI, Henry D, Pavuluri MN.
    J Child Adolesc Psychopharmacol; 2011 Dec 18; 21(6):545-53. PubMed ID: 22136096
    [Abstract] [Full Text] [Related]

  • 19. Pharmacotherapy of attention-deficit hyperactivity disorder: common quandaries, dilemmas and challenges.
    Mosheva M, Dar N, Rima Madi L, Weizman A, Gothelf D.
    Int Clin Psychopharmacol; 2020 Nov 18; 35(6):300-304. PubMed ID: 32694317
    [Abstract] [Full Text] [Related]

  • 20. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy.
    Blader JC, Schooler NR, Jensen PS, Pliszka SR, Kafantaris V.
    Am J Psychiatry; 2009 Dec 18; 166(12):1392-401. PubMed ID: 19884222
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.